Medicine & Life Sciences
Glioblastoma
100%
Glioma
70%
Temozolomide
67%
Survival
45%
Radiation
33%
Lymphopenia
32%
Neoplasms
29%
Lymphocyte Count
26%
Radiotherapy
25%
Brain Neoplasms
22%
Radiosurgery
21%
Therapeutics
19%
Intracranial Arteriovenous Malformations
16%
Progression-Free Survival
15%
Recurrence
15%
Maximum Tolerated Dose
12%
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
12%
Brain
11%
Cilengitide
11%
iniparib
11%
Methotrexate
11%
Safety
11%
Breast Neoplasms
11%
Arteriovenous Malformations
11%
Drug Therapy
11%
Bevacizumab
11%
Immunity
10%
Lymphoma
10%
Rituximab
9%
Granulocyte-Macrophage Colony-Stimulating Factor
9%
Central Nervous System
9%
Pharmacokinetics
9%
Pharmaceutical Preparations
8%
Cerebral Palsy
8%
Multiple Myeloma
8%
Neurofibromatosis 2
8%
Cyclophosphamide
8%
Confidence Intervals
7%
Monoclonal Antibodies
7%
Neoplasm Metastasis
7%
Sorafenib
7%
Cancer Vaccines
7%
Clinical Trials
7%
Carotid Endarterectomy
7%
GYKI 53405
6%
Medicine
6%
T-Lymphocytes
6%
poly ICLC
6%
Biomarkers
6%
Astrocytoma
6%